Stereotaxis (STXS): Price and Financial Metrics
STXS Stock Summary
- The ratio of debt to operating expenses for Stereotaxis Inc is higher than it is for about just 16.56% of US stocks.
- STXS's price/sales ratio is 22.57; that's higher than the P/S ratio of 90.67% of US stocks.
- The volatility of Stereotaxis Inc's share price is greater than that of 77.08% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to STXS, based on their financial statements, market capitalization, and price volatility, are TUFN, OOMA, LC, YY, and PGEN.
- STXS's SEC filings can be seen here. And to visit Stereotaxis Inc's official web site, go to www.stereotaxis.com.
STXS Stock Price Chart Interactive Chart >
STXS Price/Volume Stats
|Current price||$8.00||52-week high||$8.62|
|Prev. close||$8.15||52-week low||$3.03|
|Day high||$8.22||Avg. volume||375,099|
|50-day MA||$6.89||Dividend yield||N/A|
|200-day MA||$4.81||Market Cap||592.64M|
Stereotaxis (STXS) Company Bio
Stereotaxis Inc. designs, manufactures, and markets advanced cardiology instrument control system for use in the cath lab that is used in the treatment of coronary artery disease and arrhythmias. The Company markets Stereotaxis System in the United States and Europe.
STXS Latest News Stream
|Loading, please wait...|
STXS Latest Social Stream
View Full STXS Social Stream
Latest STXS News From Around the Web
Below are the latest news stories about Stereotaxis Inc that investors may wish to consider to help them evaluate STXS as an investment opportunity.
ST. LOUIS, April 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chairman and CEO, will serve as the keynote speaker at the Robotic Surgery & Enabling Technologies Virtual Summit 2021. The presentation will take place on Thursday, April 15, 2021. Mr. Fischel will focus his discussion on the current clinical and technological frontiers of robotic surgery. “We are excited for David to share his broad perspective on what the robotic surgery community has accomplished and the significant areas of opportunity ahead of us,” says Dr. Emir Osmanagic, Chairman of The Summit and Director of Digital Surgery at Johnson & Johnson. “I am honored to be able to join Dr. Os...
Broward Health Medical Center Becomes First Hospital in Florida to Adopt Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders
ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medical Center is establishing a robotic electrophysiology program to expand access to advanced minimally-invasive treatment of heart rhythm disorders in Florida. Broward Health Medical Center will be the only hospital in South Florida offering robotic technology to treat patients suffering from arrhythmias and is the first in Florida, and among the first in the nation, to adopt the latest Genesis Robotic Magnetic Navigation system. “The adoption of this advanced robotic technology further reinforces the commitment Broward Health Medical Center has toward providing high quality cardiac care fo...
ST. LOUIS, March 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it will move its global headquarters to the Globe Building in downtown St. Louis at the end of this year. “Establishing our new headquarters at the Globe is another exciting step in our effort to modernize every aspect of Stereotaxis and build a foundation to support years of significant growth,” says David Fischel, Stereotaxis Chairman and CEO. “Our new space is being designed to support improved collaboration across an expanding team along with a three-fold expansion of our surgical robot manufacturing capacity.” Referred to as “The Hi-Tech Castle,” the Globe Building is located in downtown St. Louis’ Inn...
Stereotaxis Inc. (STXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
STXS earnings call for the period ending December 31, 2020.
STXS Price Returns
Continue Researching STXSWant to see what other sources are saying about Stereotaxis Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!